Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 known ✓ | Q9H244 | 1/20 | 0.43 |
| ▸ | THRB known ✓ | P10828 | 3/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.44 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.44 |
| ▸ | TST | Q16762 | 2/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1459623 | 1.00 | NR4A1 (0.57) | NR4A1AURKAAURKBCYP1A2HSPD1 | |
| SCHEMBL30683823 | 0.94 | NR4A1 (0.57) | NR4A1AURKAAURKBCYP1A2HSPD1 | |
| SCHEMBL8508834 | 0.93 | NR4A1 (0.61) | NR4A1AURKAAURKBCYP1A2HSPD1 | |
| SCHEMBL16446112 | 0.93 | NR4A1 (0.61) | NR4A1AURKAAURKBCYP1A2HSPD1 | |
| SCHEMBL31709341 | 0.93 | NR4A1 (0.61) | NR4A1AURKAAURKBCYP1A2HSPD1 | |
| SCHEMBL29664225 | 0.93 | NR4A1 (0.61) | NR4A1AURKAAURKBCYP1A2HSPD1 | |
| Water SCHEMBL12275144 | 0.91 | NR4A1 (0.60) | NR4A1AURKAAURKBCYP1A2HSPD1 | |
| Lithium Ion SCHEMBL155096 | 0.90 | NR4A1 (0.61) | NR4A1AURKAAURKBCYP1A2HSPD1 | |
| SCHEMBL156055 | 0.90 | AURKB (0.64) | NR4A1AURKAAURKBCYP1A2KDM4E | |
| SCHEMBL29608931 | 0.90 | AURKB (0.64) | NR4A1AURKAAURKBCYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382329-A1 | INTERMEDIATE USED FOR FAPI SYNTHESIS, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | YANTAI LANNACHENG BIOTECHNOLOGY CO LTD (CN) | 2025-12-18 | — | — | US | claimed |
| US-20250332299-A1 | COMPOUND TARGETING SSTR2, PREPARATION METHOD THEREFOR AND USE THEREOF | YANTAI LANNACHENG BIOTECHNOLOGY CO LTD (CN) | 2025-10-30 | — | — | US | claimed |
| EP-4613758-A1 | COMPOUNDS TARGETING SSTR2, PREPARATION METHOD THEREFOR, AND USE THEREOF | Yantai Lannacheng Biotechnology Co., Ltd. (CN) | 2025-09-10 | — | — | EP | claimed |
| EP-4585607-A1 | INTERMEDIATE USED FOR FAPI SYNTHESIS, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Yantai Lannacheng Biotechnology Co., Ltd. (CN) | 2025-07-16 | — | — | EP | claimed |
| WO-2024169973-A1 | INTERMEDIATE USED FOR FAPI SYNTHESIS, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 烟台蓝纳成生物技术有限公司 | 2024-08-22 | — | — | WO | claimed |
| WO-2024120415-A1 | COMPOUNDS TARGETING SSTR2, PREPARATION METHOD THEREFOR, AND USE THEREOF | 烟台蓝纳成生物技术有限公司 | 2024-06-13 | — | — | WO | claimed |
| CN-115838393-B | Intermediate for FAPI synthesis and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-115838393-A | Intermediate for FAPI synthesis and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2023-03-24 | — | — | CN | claimed |
| CN-115583989-B | SSTR 2-targeted compound and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2023-02-28 | — | — | CN | claimed |
| CN-113429417-B | Method for preparing camptothecin and evans blue coupled amphiphilic compound | 烟台蓝纳成生物技术有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-115583989-A | SSTR 2-targeted compound and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2023-01-10 | — | — | CN | claimed |
| CN-115161324-A | Evans blue modified EpCAM-targeted nucleic acid aptamer and preparation method and application thereof | 中国人民解放军空军军医大学 | 2022-10-11 | — | — | CN | claimed |
| WO-2022170732-A1 | TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海蓝纳成生物技术有限公司 | 2022-08-18 | — | — | WO | claimed |
| EP-3755321-B1 | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER | US HEALTH (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250382329-A1 | INTERMEDIATE USED FOR FAPI SYNTHESIS, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | YANTAI LANNACHENG BIOTECHNOLOGY CO LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| US-20250332299-A1 | COMPOUND TARGETING SSTR2, PREPARATION METHOD THEREFOR AND USE THEREOF | YANTAI LANNACHENG BIOTECHNOLOGY CO LTD (CN) | 2025-10-30 | — | — | US | disclosed |
| CN-109153641-B | Chemical conjugates of evans blue derivatives and their use as radiotherapeutic and imaging agents | 美国政府健康及人类服务部 | 2022-10-18 | — | — | CN | disclosed |
| CN-115161324-A | Evans blue modified EpCAM-targeted nucleic acid aptamer and preparation method and application thereof | 中国人民解放军空军军医大学 | 2022-10-11 | — | — | CN | disclosed |
| WO-2022170732-A1 | TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海蓝纳成生物技术有限公司 | 2022-08-18 | — | — | WO | disclosed |
| CN-113476404-B | Self-assembled nano-vesicle medicine and preparation method and application thereof | 上海蓝纳成生物技术有限公司 | 2022-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332299-A1 | COMPOUND TARGETING SSTR2, PREPARATION METHOD THEREFOR AND USE THEREOF | SSTR2, SSTR5, SSTR3 | P2RY12 2312/4885THRB 246/4885NR4A1 2528/4885 |
| US-20250382329-A1 | INTERMEDIATE USED FOR FAPI SYNTHESIS, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | FAP, ALPI, HADHB | P2RY12 3401/4885THRB 4732/4885NR4A1 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.